Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H18N4O2 |
| Molecular Weight | 334.3718 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C4=NNC(=O)CC4C
InChI
InChIKey=GLBJJMFZWDBELO-UHFFFAOYSA-N
InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
| Molecular Formula | C19H18N4O2 |
| Molecular Weight | 334.3718 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1660359
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1660359
Pimobendan (INN, or pimobendane; tradenames Vetmedin, Acardi, and Heartmedin) is a veterinary medication. Under the trade name Acardi, it is available for human use in Japan. Usually, this medicine is used to treat acute heart failure and chronic heart failure (mild to moderate in severity). By increasing the calcium ion sensitivity to protein regulating myocardial contraction and also by inhibiting phosphodiesterase (PDE-III) activity, this medicine dilates the blood vessels and improves the symptoms of heart failure such as shortness of breath and difficulty in breathing. Pimobendan is metabolized into an active metabolite (desmethylpimobendan) by the liver. The parent compound, pimobendan, is a potent calcium sensitizer while desmethylpimobendan is a more potent phosphodiesterase III inhibitor. Pimobendan is 90–95% bound to plasma proteins in circulation. This may have implications in patients suffering from low blood protein levels (hypoproteinemia/hypoalbuminemia) and in patients that are on concurrent therapies that are also highly protein bound.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Differential modulation of cytokine production by drugs: implications for therapy in heart failure. | 1996 Dec |
|
| The novel insulinotropic mechanism of pimobendan: direct enhancement of the exocytotic process of insulin secretory granules by increased Ca2+ sensitivity in beta-cells. | 1998 Mar |
|
| Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. | 2001 Feb |
|
| Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status. | 2002 Dec |
|
| [Pharmacological treatment of heart failure]. | 2003 Apr |
|
| [Inotropic agents]. | 2003 May |
|
| The role of Ca++-sensitizers for the treatment of heart failure. | 2003 Oct |
|
| Use of pimobendan in the management of heart failure. | 2004 Sep |
|
| [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency]. | 2005 Apr 15 |
|
| Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. | 2005 Mar |
|
| A review of levosimendan in the treatment of heart failure. | 2006 |
|
| Positive inotropic effect of purified green tea catechin derivative in guinea pig hearts: the measurements of cellular Ca2+ and nitric oxide release. | 2006 Dec 15 |
|
| Syncope secondary to transient atrioventricular block in a German shepherd dog with dilated cardiomyopathy and atrial fibrillation. | 2006 May |
|
| [Subarachnoid hemorrhage complicated with different manifestations of transient abnormal left ventricular wall motion: two case reports]. | 2006 May |
|
| Preclinical dilated cardiomyopathy in the dobermann. | 2006 May 27 |
|
| Acute heart failure: inotropic agents and their clinical uses. | 2006 Nov |
|
| New insights in the treatment strategy for pulmonary arterial hypertension. | 2006 Oct |
|
| A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure. | 2007 Aug |
|
| Translational medicine with a capital T, troponin T, that is. | 2007 Jul 20 |
|
| Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. | 2007 Jul 20 |
|
| The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates. | 2007 Sep-Oct |
|
| Effect of short-term treatment with meloxicam and pimobendan on the renal function in healthy beagle dogs. | 2008 Apr |
|
| Cardiac Ca2+ signaling and Ca2+ sensitizers. | 2008 Dec |
|
| Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. | 2008 Jul-Aug |
|
| Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients. | 2008 Mar |
|
| Alterations in vasomotor control of coronary resistance vessels in remodelled myocardium of swine with a recent myocardial infarction. | 2008 May |
|
| Canine heart disease: progress and promise. | 2008 Nov |
|
| Treatment of congestive heart failure in dogs. | 2008 Oct 25 |
|
| A QUEST begins. | 2008 Sep-Oct |
|
| Chronic cor pulmonale secondary to pulmonary atherosclerosis in an African Grey parrot. | 2009 Apr 15 |
|
| Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. | 2009 Mar-Apr |
|
| Transient tricuspid valve regurgitation following surgical treatment of cor triatriatum dexter in a dog. | 2009 May |
|
| Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: an evaluation of the QA interval as an indirect indicator of cardiac inotropism. | 2009 Sep-Oct |
|
| Sarcomere control mechanisms and the dynamics of the cardiac cycle. | 2010 |
|
| Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. | 2010 Feb |
|
| Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities. | 2010 Jan |
|
| Human cardiac tissue in a microperfusion chamber simulating extracorporeal circulation--ischemia and apoptosis studies. | 2010 Jan 18 |
|
| Current use of pimobendan in canine patients with heart disease. | 2010 Jul |
|
| Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives. | 2010 Jun 1 |
|
| Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. | 2013 Dec |
Sample Use Guides
Acute heart failure: usually for adults, one capsule (2.5 mg of pimobendan) once daily
Chronic heart failure (mild to moderate in severity): usually for adults, one capsule (2.5 mg of pimobendan) twice daily after meals
Route of Administration:
Oral
composite platelet aggregation (area under the curve [AUC]) and maximal platelet aggregation (aggregation units [AUs]) at 10.0μM pimobendan were significantly decreased for collagen-induced aggregation (AUC, 349.7 ± 58.4 vs 285.1 ± 72.2; maximal platelet aggregation, 196.2 ± 25.8 AUs vs 161.5 ± 38.0 AUs), and the AUC and velocity of aggregation at 10.0μM pimobendan were significantly decreased for ADP-induced aggregation (AUC, 268.5 ± 35.1 vs 213.4 ± 77.2; velocity of aggregation, 15.7 ± 2.9 AUs/min vs 11.8 ± 3.5 AUs/min).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:16:24 GMT 2023
by
admin
on
Fri Dec 15 15:16:24 GMT 2023
|
| Record UNII |
34AP3BBP9T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.1780
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
FORTEKOR PLUS (AUTHORISED)
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
34AP3BBP9T
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
PIMOBENDAN
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
DD-18
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
SUB09845MIG
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
118428-36-7
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
SUPERSEDED | |||
|
1569315
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL24646
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
100000081974
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
2171
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
C041648
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
m8815
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
34AP3BBP9T
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
DB11450
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
C82305
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
74150-27-9
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
5090
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
1110783
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
4823
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
32003
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY | |||
|
DTXSID8048280
Created by
admin on Fri Dec 15 15:16:24 GMT 2023 , Edited by admin on Fri Dec 15 15:16:24 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
IMPURITY -> PARENT | |||
|
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
